biostudies-literatureZong YScience, Technology and Innovation Commission of Shenzhen MunicipalityBasic and Applied Basic Research Foundation of Guangdong ProvinceNational Natural Science Foundation of ChinaNational Key Research and Development Program of China20376-20381https://www.ebi.ac.uk/biostudies/studies/S-EPMC12489802biostudies-literatureUnknown16(43)A catalytic protocol for the iridium-catalyzed dynamic kinetic resolution asymmetric hydrogenation (DKR-AH) of α-substituted tetralones to rapidly assemble various enantioenriched tetrahydronaphthols is disclosed. A wide range of enantioenriched tetrahydronaphthols were obtained in high yields and excellent stereoselectivities (up to 99% yield, up to >99.5 : 0.5 er and >20 : 1 dr). And this unique platform exhibited high efficiency for the enantioselective synthesis of (+)-elacestrant, which was approved by the FDA in 2023 for the treatment of metastatic breast cancer. Additionally, palladium-catalyzed amination of aryl chloride assisted in furnishing the gram-scale synthesis of this oral anti-tumor drug within 7 steps in 43% yield.Chemical scienceGram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones.PMC1248980222171129JCYJ202408130951060092022B15150200552021YFA1500200223020902022A151511009321991113Zou XZong YChen GQZhang XZhang SfalseGram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones.A catalytic protocol for the iridium-catalyzed dynamic kinetic resolution asymmetric hydrogenation (DKR-AH) of α-substituted tetralones to rapidly assemble various enantioenriched tetrahydronaphthols is disclosed. A wide range of enantioenriched tetrahydronaphthols were obtained in high yields and excellent stereoselectivities (up to 99% yield, up to >99.5 : 0.5 er and >20 : 1 dr). And this unique platform exhibited high efficiency for the enantioselective synthesis of (+)-elacestrant, which was approved by the FDA in 2023 for the treatment of metastatic breast cancer. Additionally, palladium-catalyzed amination of aryl chloride assisted in furnishing the gram-scale synthesis of this oral anti-tumor drug within 7 steps in 43% yield.2025-01-01T00:00:00Z2025 Nov2026-06-05T11:39:22.936Z2026-05-16T03:12:57.291ZS-EPMC124898024105057310.1039/d5sc05497d